SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

However, the analysts believe Novo Nordisk’s current valuation—trading at just 21 times their projected 2026 earnings—presents an attractive entry point. With the REDEFINE 1 data expected to validate ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The stock is now heading for an eye-popping annual gain of over ... First, let's consider some background on this specific ...

Novo Nordisk (NVO) has released an update. Novo Nordisk announced that its board members and executives have sold a significant volume of ...

Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

I think the picture is murky after this, although overall Novo Nordisk maybe, even though the stock is down a little bit this year, maybe those numbers reassured investors a little bit about the near ...

The company's latest presentation supports the idea that its lead program will make billions.

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as ...